Presenting CVRx at the Canaccord Genuity 42nd Annual Growth Conference

Presenting CVRx at the Canaccord Genuity 42nd Annual Growth Conference


MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical technology company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients suffering from cardiovascular disease, announced today that the management team will be presenting at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022. The Company is scheduled to webcast the same day at 8:30 am Eastern Time.

A live audio webcast of the conference presentation will be available online on the Investor Relations page of the Company’s website or the link here.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first FDA-cleared medical technology that uses neuromodulation to improve symptoms in heart failure patients. Barostim is an implantable device that delivers electrical impulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy aims to restore the balance of the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim has received FDA Breakthrough Device designation and is FDA cleared for use in heart failure patients in the United States. It has also received the CE mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit

Investor contact:

Mark Klausner or Mike Vallie
ICR Westwicke

Media contact:

Erich Sandowal
Finnish partners


Source story

More to explorer